Centessa Pharmaceuticals (CNTA) Cash from Investing Activities (2021 - 2026)

Centessa Pharmaceuticals (CNTA) has 6 years of Cash from Investing Activities data on file, last reported at $42.7 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $42.7 million, up 119.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$153.4 million (up 26.19% YoY), and the FY2025 annual result was -$418.5 million, down 1438.57% from the prior year.
• Cash from Investing Activities grew to $42.7 million in Q1 2026 per CNTA's latest filing, from -$218.1 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $61.9 million in Q3 2025 and troughed at -$222.4 million in Q1 2025.
• A 5-year average of -$27.8 million and a median of -$240000.0 in 2022 frame the typical range for Cash from Investing Activities.
• On a YoY basis, Cash from Investing Activities climbed as much as 304512.5% in 2023 and fell as far as 35873.33% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$446000.0 in 2022, then plunged by 3997.53% to -$18.3 million in 2023, then jumped by 236.8% to $25.0 million in 2024, then tumbled by 972.54% to -$218.1 million in 2025, then jumped by 119.58% to $42.7 million in 2026.
• Business Quant data shows CNTA's Cash from Investing Activities at $42.7 million in Q1 2026, -$218.1 million in Q4 2025, and $61.9 million in Q3 2025.